title: Expression of maspin and kai1 and their clinicopathological significance in carcinogenesis and progression of gastric cancer.
abstract: OBJECTIVE
  To investigate the roles of maspin and kai1 expression in tumorigenesis and progression of gastric cancer.
  
  
  METHODS
  Maspin and kai1 expressions were detected in normal gastric mucosa (n = 182), gastric dysplasia (n = 69), and gastric cancer (n = 113) by immunohisto-chemistry. Their expressions were compared with clinicopathological parameters of tumors. Relationship between maspin and kai1 expression was also concerned in gastric cancer.
  
  
  RESULTS
  The positive rates of maspin expression were 79.8% (145/182), 75.4% (52/69), and 50.4% (57/113) in normal gastric mucosa, gastric dysplasia, and gastric cancer, while those of kai1 expression were 81.9% (149/182), 65.2% (49/69), and 58.4% (66/113) in corresponding tissues respectively. Gastric cancer less frequently expressed maspin than the normal gastric mucosa and gastric dysplasia (P < 0.05), while dysplasia and cancer showed less frequent expression of kai1 than normal mucosa (P < 0.05). Maspin expression showed negative association with invasive depth, metastasis, Lauren's and histological classifications (P < 0.05), but not with tumor size, Borrmann's classification, growth pattern or TNM staging (P > 0.05). Kai1 expression was negatively correlated with invasive depth, metastasis, growth pattern, Lauren's and histological classifications (P < 0.05), but not with tumor size, Borrmann's classification or TNM staging (P > 0.05). Maspin and kai1 were collaboratively expressed in gastric cancer (P < 0.05).
  
  
  CONCLUSIONS
  Down-regulated expressions of maspin and kai1 play an important role in gastric carcinogenesis. Abnormal expression of maspin and kai1 might have inhibitory effects on invasion and metastasis of gastric cancer and act as an effective and objective marker to indicate the pathobiological behaviors of gastric cancer.
authors.affiliation: The Fourth Laboratory, Cancer Institute, the First Affiliated Hospital of China Medical University, Shenyang 110001. zheng_huachuan@hotmail.com
authors.forename: Hua-chuan
authors.initials: HC
authors.lastname: Zheng
authors.forename: Meng-chun
authors.initials: MC
authors.lastname: Wang
authors.forename: Jin-yi
authors.initials: JY
authors.lastname: Li
authors.forename: Xue-fei
authors.initials: XF
authors.lastname: Yang
authors.forename: Jin-min
authors.initials: JM
authors.lastname: Sun
authors.forename: Yan
authors.initials: Y
authors.lastname: Xin
mesh_terms: D000230:Adenocarcinoma / Q000378:metabolism*; D015703:Antigens, CD / Q000378:metabolism*; D014408:Biomarkers, Tumor; D015197:Carcinogenicity Tests; D016147:Genes, Tumor Suppressor; D006801:Humans; D006965:Hyperplasia / Q000378:metabolism; D051861:Kangai-1 Protein; D008207:Lymphatic Metastasis; D008562:Membrane Glycoproteins / Q000378:metabolism*; D009361:Neoplasm Invasiveness; D009367:Neoplasm Staging; D011506:Proteins / Q000378:metabolism*; D011518:Proto-Oncogene Proteins / Q000378:metabolism*; D015843:Serpins / Q000378:metabolism*; D013270:Stomach / Q000473:pathology; D013274:Stomach Neoplasms / Q000378:metabolism*
chemical_list: D015703:Antigens, CD; D014408:Biomarkers, Tumor; C497688:CD82 protein, human; D051861:Kangai-1 Protein; D008562:Membrane Glycoproteins; D011506:Proteins; D011518:Proto-Oncogene Proteins; C085344:SERPIN-B5; D015843:Serpins